All In Biotech

Drug Trial Radar · NCT06247605

A Phase IIII Study of AL8326 in Small Cell Lung Cancer

Phase III Clinical Study of AL8326 Tablets in Patients With Advanced or Recurrent Small Cell Lung Cancer After at Least Prior Second-line Treatment

Last checked: Nov 19, 2026Latest source record: Feb 8, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 243 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

243

Planned (sponsor's estimate)

Start

Oct 26, 2023

Primary completion

Jul 2028

Study completion Jul 2029

Sponsor

Sponsor type
Industry
First posted
Feb 8, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, double-blind, placebo-controlled, phase III study to evaluate the efficacy and safety of AL8326 tablets in small cell lung cancer (SCLC) patients with disease progression or recurrence after receiving at least second-line treatment regimens.

Conditions

  • Small Cell Lung Carcinoma

Interventions

  • AL8326 tabletsDrug

    10mg/tablet, Oral administration, once daily.

  • placeboDrug

    Oral administration, once daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall survival (OS)Time frame: Cycle 1 Day 1 up to 3 years (each cycle is 28 days)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • JILIN Cancer Hospital

    Changchun, Jilin, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.